Fig. 3: Repeatedly high-level EBNA-1381-452-specific IgG antibody titers over time predict the diagnosis of MS. | Nature Communications

Fig. 3: Repeatedly high-level EBNA-1381-452-specific IgG antibody titers over time predict the diagnosis of MS.

From: Early identification of individuals at risk for multiple sclerosis by quantification of EBNA-1381-452-specific antibody titers

Fig. 3

EBNA-1381-452-specific IgG antibody titers from N = 324 MS patients and N = 324 controls were quantified at time point of EBV seroconversion, median 8.9 months after EBV seroconversion (time point 1), median 17.8 months after EBV seroconversion (time point 2), median 26.9 months after EBV seroconversion (time point 3), and median 36 months after EBV seroconversion (time point 4). The number of MS patients and controls with high-level EBNA-1381-452-specific IgG antibody titers (OD ≥ 1.7), was then assessed for time point 1, time point 2, time point 3 and time point 4. A Data are shown as the cumulative number of time points with high-level EBNA-1381-452-specific IgG antibody titers. Groups were compared using the Chi-square test. B The time point of MS diagnosis was compared to the cumulative numbers of time points with high-level EBNA-1381-452-specific IgG antibody titers using the two-sided Gehan-Breslow-Wilcoxon Test. C The time point of MS disease onset was compared to the cumulative numbers of time points with high-level EBNA-1381-452-specific IgG antibody titers using the two-sided Gehan-Breslow-Wilcoxon Test. EBNA-1: Epstein–Barr Virus Nuclear Antigen 1, EBV: Epstein-Barr virus, MS: Multiple Sclerosis, T: Time point.

Back to article page